Recent

% | $
Quotes you view appear here for quick access.

Albany Molecular Research Inc. Message Board

yummyrutabaga 12 posts  |  Last Activity: Mar 3, 2006 10:11 PM Member since: Nov 1, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • yummyrutabaga by yummyrutabaga Mar 3, 2006 10:11 PM Flag

    Has anyone ever seen a longer list of certain forward looking statements at the end of an earnings release? Oddly, there's no mention of the potential impact of their purported nanotechnology (as described by numerous posts here on this msg. board) turning into picoearnings.

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include, but are not limited to, statements regarding the company's estimates of contract revenue for the first quarter of 2006 and for the full year 2006, statements made by the company's chief executive officer and chief financial officer, statements regarding the company's real property tax credit, the company's overseas operations, the license agreement with Bristol-Myers Squibb Company, the strength of the company's business, the patent infringement case related to Allegra and management's initiatives to sustain the company's momentum and long-term growth. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to, the existence of deficiencies and/or material weaknesses in the company's internal controls over financial reporting, the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing chemical research and development, including continued softness in these markets, sales of Allegra and the company's receipt of significant royalties from the Allegra license agreement, the risk that Allegra may be approved for over-the-counter use, the over-the-counter sale of Claritin, the over-the-counter sale of generic alternatives for the treatment of allergies and the risk of new product introductions for the treatment of allergies including generic forms of Allegra, the success of the company's collaboration with Bristol-Myers Squibb Company related to biogenic amine reuptake inhibitors, the company's ability to enforce its intellectual property and technology rights, the company's ability to successfully develop novel compounds and lead candidates in its collaborative arrangements, the company's ability to take advantage of proprietary technology and expand the scientific tools available to it, the ability of the company's strategic investments and acquisitions to perform as expected, including the possibility that the company's proposed acquisition of ComGenex will not close, that the closing may be delayed or that the companies may be required to modify aspects of the acquisition to close the acquisition, the satisfaction of closing conditions to the acquisition, the reaction of customers of the company and ComGenex to the acquisition, the company's timing and ability to successfully integrate ComGenex' operations (including migration of ComGenex to the company's systems and controls) and employees, the introduction of new services by competitors or the entry of new competitors into the markets for the company's and ComGenex' services, the failure by the company to retain key employees of ComGenex, failure to further develop and successfully market ComGenex' service offerings, failure to achieve anticipated revenues and earnings, costs related to the acquisition and any goodwill impairment related to such investments and acquisitions, the risks posed by international operations to the company, and the company's ability to effectively manage its growth, as well as those discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2004 as filed with the Securities and Exchange Commission on March 16, 2005,...

  • Reply to

    Insider dispositions

    by thirdwilson Feb 13, 2006 4:22 PM
    yummyrutabaga yummyrutabaga Feb 28, 2006 11:01 PM Flag

    Oops, I meant to write Albanization, not Alabnization but u get the point. Apologies to all those who otherwise would view this message board as the gold standard.

  • Reply to

    Insider dispositions

    by thirdwilson Feb 13, 2006 4:22 PM
    yummyrutabaga yummyrutabaga Feb 28, 2006 10:52 PM Flag

    Good questions, pharmageek. I don't have any good answers. Maybe everyone is awaiting the results of the Alabnization of the soon-to-be HRC (Hungarian Research Center)before passing judgment.

  • Reply to

    for all you longs

    by chemmavin May 13, 2005 12:39 PM
    yummyrutabaga yummyrutabaga May 18, 2005 11:09 PM Flag

    Hey amrithebest, I can hardly wait for your next psychotropic epiphany about the sensatinal future for this company. Whatever you "mentor" your reports with I hope there's enough to go around for everybody.

  • Reply to

    Time to buy is now!

    by dagvc1 Mar 3, 2005 3:25 PM
    yummyrutabaga yummyrutabaga Mar 4, 2005 9:39 PM Flag

    "9 new compounds are in 3rd clinical trials. 2 already have customers ready to buy them. Good luck to all"??????????????

    Are you sure you were listening to the AMRI conferecne call and not the PFE call? Nine compounds in phase 3 trials? Their own or someone else's?

  • Reply to

    Time to buy is now!

    by dagvc1 Mar 3, 2005 3:25 PM
    yummyrutabaga yummyrutabaga Mar 3, 2005 9:16 PM Flag

    Was the music that you heard during the conference call the song titled "Road to Nowhere"?

  • yummyrutabaga by yummyrutabaga Jan 25, 2005 10:20 PM Flag

    Anyone know whatever happened with the proposed establishment of an Albany Molecular Research Hyderabad Research Center (AMRHRC)? Maybe AMRI is afraid that their patent on yahoo management principles will be violated.

  • Reply to

    getting overbought

    by wdblawgrow Nov 5, 2004 1:50 PM
    yummyrutabaga yummyrutabaga Nov 23, 2004 2:38 PM Flag

    You heard that employees are not being allowed to post on these boards? Amazing. I suppose they are not allowed to say anything constructive at work either or they'll be scolded for having a negative attitude.

  • Reply to

    getting overbought

    by wdblawgrow Nov 5, 2004 1:50 PM
    yummyrutabaga yummyrutabaga Nov 19, 2004 5:17 PM Flag

    Well put. "amrithebest" sure does not seem normal. Maybe "amrithebest" will buy that bridge in Brooklyn.

  • Reply to

    Good call Alints_200 When would

    by pirates144 Nov 8, 2004 10:12 PM
    yummyrutabaga yummyrutabaga Nov 10, 2004 10:05 PM Flag

    Yes, it is strange that there has been no press release. Not familiar with the Chemical and Engineering News magazine but wonder, given their recent financial performance, if something like the Journal of Irreproducible Results would be more appropriate???

  • Reply to

    Good call Alints_200 When would

    by pirates144 Nov 8, 2004 10:12 PM
    yummyrutabaga yummyrutabaga Nov 9, 2004 9:47 PM Flag

    Let's not forget Singapore either. Where next? Any other good cultural fits left out there? England? Ireland? China?

  • Reply to

    anyone know what earnings might be like

    by dagvc Oct 29, 2004 6:32 PM
    yummyrutabaga yummyrutabaga Nov 1, 2004 5:01 PM Flag

    New products? Like what? A new drug to instill the corporate culture in Hyderabad?

AMRI
19.84+0.24(+1.22%)3:45 PMEDT